Previous close | 3.0000 |
Open | N/A |
Bid | 3.0000 |
Ask | 3.8000 |
Strike | 17.50 |
Expiry date | 2025-01-17 |
Day's range | 3.0000 - 3.0000 |
Contract range | N/A |
Volume | |
Open interest | 79 |
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
DUBLIN, May 28, 2024--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.
Celebrations may be in order for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, with the analysts delivering a...